echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > The Production Process of Flupenthixol dihydrochloride

    The Production Process of Flupenthixol dihydrochloride

    • Last Update: 2023-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Flupenthixol dihydrochloride is an atypical antipsychotic medication that is commonly used to treat schizophrenia and other psychiatric disorders.
    The production process of flupenthixol dihydrochloride involves several stages, including the synthesis of the precursor compound, the extraction and purification of the active ingredient, and the formulation of the final product.


    1. Synthesis of the Precursor Compound

    The synthesis of the precursor compound, known as dihydrochloride, is the first step in the production process of flupenthixol dihydrochloride.
    This step involves the reaction of several chemicals, including phenylisopropylamine, aniline, and formaldehyde.
    The reaction is carried out in several stages, with the reaction mixture being heated and stirred to promote the reaction.


    1. Extraction and Purification of the Active Ingredient

    Once the precursor compound has been synthesized, it is necessary to extract and purify the active ingredient, which is flupenthixol dihydrochloride.
    This is typically done using a combination of chromatographic techniques, such as column chromatography and flash chromatography.


    During column chromatography, the precursor compound is passed through a column packed with a stationary phase, such as silica gel or alumina.
    The different components of the mixture separate as they pass through the column, with the active ingredient being eluted from the column using a solvent that is compatible with the stationary phase.


    Flash chromatography is a similar process, but it is performed using a shorter column and a more volatile solvent.
    This technique is often used to purify the active ingredient to a higher degree of purity.


    1. Formulation of the Final Product

    Once the active ingredient has been extracted and purified, it is typically formulated into a final product, such as a capsule or tablet.
    This step involves mixing the active ingredient with other ingredients, such as excipients and binders, to create a stable and consistent formulation.


    The formulation process is highly regulated, with strict guidelines governing the quality and purity of the final product.
    This ensures that the final product is safe and effective for use in patients.


    In conclusion, the production process of flupenthixol dihydrochloride involves several stages, including the synthesis of the precursor compound, the extraction and purification of the active ingredient, and the formulation of the final product.
    This process is highly regulated and must be performed in a consistent and controlled manner in order to ensure the quality and safety of the final product.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.